Quest Diagnostics to offer US FDA-approved Fujirebio blood test for Alzheimer's disease: Secaucus, New Jersey Friday, July 11, 2025, 14:00 Hrs [IST] Quest Diagnostics, a leader in ...

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced it plans to offer laboratory testing based on the ...

Data presented today at the ESHRE congress builds evidence for conventional-based Follicular Stimulating Hormone (FSH) dosing for Rekovelle (follitropin delta); alongside its existing unique algorithm ...

After decades of research, the U.S. Food and Drug Administration (FDA) has approved a test that can detect the buildup of amyloid plaques in the brain—a key marker of Alzheimer’s disease, ...

The FDA label update boosts GE HealthCare’s Vizamyl to a market advantage despite the emergence of blood-based tests.

Research into Alzheimer’s diagnosis is gaining momentum amid the revenue ceiling for anti-amyloid therapies. Last month, the FDA approved the Lumipulse G test, the first blood test to help diagnose ...

The Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio test is an accurate, minimally invasive, accessible measurement of pTau 217 and β-Amyloid 1-42 concentrations in plasma as a proxy for the ...

This initiative follows the landmark FDA clearance of the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio test developed by Fujirebio Diagnostics in May 2025.

NEW YORK, June 15, 2025 /PRNewswire/ -- It is with deep sorrow and profound admiration that the Alzheimer's Drug Discovery Foundation (ADDF) shares the passing of Co-Founder and Chairman, Leonard ...

The firm's Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio is used for the measurement of pTau217 and β-amyloid 1-42 levels and calculation of the ratio between the proteins to aid the detection of ...

In patients showing cognitive decline, a new blood test for Alzheimer's is expected to make diagnosis more convenient, accessible and inexpensive than other existing tests.